Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome

Recruiting Phase 2 Interventional Study
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
150 (estimated)
Sponsor
Al-Mustansiriyah University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers w…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * • Newly diagnosed patients should be at reproductive aged from 18-40 years. * Patients diagnosed with presence of micro polycystic ovaries at ultrasound. * Oligomenorrhea with inter-menstrual intervals longer than 35 days. * Clinical or biochemical signs of hyperandroge…
Contacts

Mohammed Mahmood Mohammed, professor

7816871131

pharm.drmhdclinical@uomustansiriyah.edu.iq

CONTACT